ReviewFrontiers in bioengineering and biotechnology2020
Bacteriocins From LAB and Other Alternative Approaches for the Control of
Review in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Microbiome-based therapeutics forGut microbes · 2026Review
- Altitude-Associated Divergence of the Gut Microbiome in Endangered Forest Musk Deer: Evidence From Integrated Metagenomics, Metabolomics, and Culturomics.Evolutionary applications · 2026Article
- Restoration of the Mucosal Barrier by Lactobacillus gasseri HDS0266 and Enterococcus faecium HDS0288 in Dextran Sodium Sulfate and Clostridioides difficile-Induced Colitis Mice.Probiotics and antimicrobial proteins · 2026Article
- Probiotic characterization and spore production optimization of Lysinibacillus sp. MK212927.Applied microbiology and biotechnology · 2026Article
- Tandem solubility enhancing tags enable the heterologous expression andFrontiers in microbiology · 2026Article
- Synergistic and off-target effects of bacteriocins in a simplified human intestinal microbiome: implications forGut microbes · 2025Article
- Characterization and antimicrobial potential of bacteriocin-producing lactic acid bacteria isolated from the gut ofMicrobiology spectrum · 2025Article
- A Review on Bacteriocin Extraction Techniques from Lactic Acid Bacteria.Probiotics and antimicrobial proteins · 2025Review
- A Comprehensive Review on Preparation of Silver Nanoparticles from a Bacteriocin for the Natural Preservation of Food Products.Applied biochemistry and biotechnology · 2025Review
- Assessment of potential probiotic lactic acid bacteria in rice-based fermented products of Southern Assam, Northeast India.Frontiers in microbiology · 2025Article
- Non-invasive treatment ofFrontiers in microbiology · 2025Article
- Probiotics under Selective Pressure: Novel Insights and Biosafety Challenge.Archives of Razi Institute · 2024Review
- Selective depletion of Campylobacter jejuni via T6SS dependent functionality: an approach for improving chickens gut health.Gut pathogens · 2024Article
- Necrotic enteritis and antibiotic-free production of broiler chickens: Challenges in testing and using alternative products.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2024Review
- The functional roles of short chain fatty acids as postbiotics in human gut: future perspectives.Food science and biotechnology · 2024Review
- Biosynthesis, classification, properties, and applications ofFrontiers in microbiology · 2024Review
- Probiotic Properties and Antioxidant Activity In Vitro of Lactic Acid Bacteria.Microorganisms · 2023Article
- Bacteriocins from lactic acid bacteria and their potential clinical applications.Applied biochemistry and biotechnology · 2022Review
- Probiotic-Based Intervention in the Treatment of Ulcerative Colitis: Conventional and New Approaches.Biomedicines · 2022Review
- Development of Resistance to Clarithromycin and Amoxicillin-Clavulanic Acid inMicrobiology spectrum · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiome is considered as a promising target for future non-conventional therapeutic treatment of inflammatory and infectious diseases. The search for appropriate safe and beneficial (lactic acid bacterial and other) putative probiotic strains and/or their antimicrobial metabolites represents a challenging approach for combating several problematic and emerging infections. The process of selecting suitable strains, especially of lactic acid bacteria (LAB) with superior properties, has been accelerated and intensified during the past two decades, also thanks to recent developments in lab techniques. Currently, special focus is on the potential of antimicrobial metabolites produced by some LAB strains and their application as active therapeutic agents. The vision is to develop a scientific basis for 'biotherapeutics' as alternative to conventional approaches in both human and veterinary medicine. Consequently, innovative and promising applications of LAB to the therapeutic practice are presently emerging. An overview of the existing literature indicates that some antimicrobial metabolites such as bacteriocins, widely produced by different bacterial species including LAB, are promising biotherapeutic agents for controlling infections caused by potential pathogens, such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.